BiotechTube
Akura Medical

Akura Medical

San Diego, United States· Est.
akuramedical.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

Akura Medical is a clinical-stage medical device company targeting the large and underserved venous thromboembolism (VTE) market, specifically pulmonary embolism (PE). Its core technology is the Katana Thrombectomy System, which combines an intelligent catheter, HydroBlade jet technology, and a Sentinel console for real-time procedural insights to address limitations of existing treatments. Backed by Shifamed's innovation hub and having recently closed a $53M Series C round, the company is actively enrolling patients in a U.S. pivotal trial for PE, positioning it for potential future commercialization. Akura operates as a private, pre-revenue entity advancing a single, integrated platform through clinical development.

Venous ThromboembolismPulmonary Embolism

Technology Platform

The Katana Thrombectomy System, an integrated platform featuring an injectable catheter for access and contrast delivery, HydroBlade fluid jets for clot removal, and the Sentinel console for real-time procedural feedback on clot engagement and blood loss.

Funding History

1
Total raised:$5M
Seed$5M

Opportunities

The large and growing VTE market, with up to 900,000 U.S.
cases annually, presents a significant addressable opportunity.
There is a clear clinical need for faster, more efficient, and predictable thrombectomy devices that can handle diverse clot types, which the Katana system is designed to address.
Success in the PE indication could pave the way for expansion into the adjacent Deep Vein Thrombosis (DVT) market.

Risk Factors

The company faces high clinical and regulatory risk, as its entire value depends on the success of its ongoing pivotal trial and subsequent FDA approval.
It will also face intense competition from established players in the thrombectomy space upon any potential launch, requiring clear clinical differentiation and strong commercial execution.
As a pre-revenue company, it remains dependent on additional financing until it can generate product sales.

Competitive Landscape

Akura competes in the mechanical thrombectomy market against established companies like Inari Medical, Penumbra, and Boston Scientific. The competitive landscape is intense, with continuous innovation focused on clot removal speed, completeness, and safety (minimizing blood loss). Akura's potential differentiation lies in its integrated feedback console and catheter designed to reduce procedural steps.

More companies in Diagnostics & Precision Medicine →More companies in United States →